Consultant
Tessa Therapeutics
Foster City, California
Dr. Shih is a consultant for Tessa Therapeutics after working in Tessa as Vice President of Product Development, responsible for analytical and process development of cell therapy products, viral vectors, and biomarkers, from 2016 to 2021. From 2009 to 2015 she worked in Merck as the Director of Molecular Biomarkers and led 29 scientists skilled in immunoassays, nucleic acid-based assays and next-generation sequencing, mass spectrometry, flow cytometry, cell-based assays, IHC, and bioinformatics. Her group supported biomarker assays for early phase clinical trials, collaborated with academic leaders in biomarker discovery, and conducted target validation studies in non-human primates. From 2001 to 2008 she was with Cell Genesys developing quality control and clinical monitoring assays for phase 3 clinical trials and conducting characterization studies to answer questions from the FDA and European regulatory authorities. At Bayer Pharmaceuticals (2000-2001), she developed liquid formulations and explored novel delivery routes for biological drugs. She worked at Aventis (currently Sanofi) in various capacities, from purification, formulation, to medical device development from 1994 to 2000.
Dr. Shih received a BS in Chemistry from National Taiwan University, and a Ph.D. in Biochemistry from University of Wisconsin–Madison. She completed her post-doctoral training in Molecular Pharmacology at Stanford University.
Disclosure information not submitted.
Wednesday, October 19, 2022
9:30 AM – 10:30 AM ET